Literature DB >> 11281369

How hydrocortisone substitution influences the quality of life and the bone metabolism of patients with secondary hypocortisolism.

M Wichers1, W Springer, F Bidlingmaier, D Klingmüller.   

Abstract

BACKGROUND: Even in the setting of chronic glucocorticoid substitution in hypocortisolaemic patients, severe side-effects will eventually occur when the dosage is inappropriately high. This study evaluates the effect of usual hydrocortisone substitution dosages on the well-being of the patients and on parameters of the bone metabolism to establish an optimum substitution dosage.
DESIGN: In a double blind study nine patients with secondary hypocortisolism, being divided in three groups of three, received different doages of hydrocortisone (15, 20, 30 mg per day). Well-being was assessed using three different, validated questionnaires. Markers of bone metabolism were measured in blood and urine.
RESULTS: The patients' quality of life was not impaired even at low dosages of hydrocortisone (15 or 20 mg per day). Of all laboratory parameters only osteocalcin significantly changed, decreasing at higher dosages.
CONCLUSIONS: Our study shows that a risk of bone loss may be avoided with a substitution dosage of 20 mg or even 15 mg hydrocortisone per day, without influencing the well-being of the patient.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11281369     DOI: 10.1046/j.1365-2362.2000.0300s3055.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  2 in total

1.  Therapy-Induced Growth and Sexual Maturation in a Developmentally Infantile Adult Patient with a PROP1 Mutation.

Authors:  Ludmila Brunerova; Ivana Cermakova; Bozena Kalvachova; Jana Skrenkova; Renata Poncova; Petr Sedlak
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-13       Impact factor: 5.555

2.  The contribution of serum cortisone and glucocorticoid metabolites to detrimental bone health in patients receiving hydrocortisone therapy.

Authors:  Rosemary Dineen; Lucy-Ann Behan; Grainne Kelleher; Mark J Hannon; Jennifer J Brady; Bairbre Rogers; Brian G Keevil; William Tormey; Diarmuid Smith; Christopher J Thompson; Malachi J McKenna; Wiebke Arlt; Paul M Stewart; Amar Agha; Mark Sherlock
Journal:  BMC Endocr Disord       Date:  2020-10-10       Impact factor: 2.763

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.